Source: Onclive. June 2025
Key Takeaways
- The triplet regimen of encorafenib, binimetinib, and nivolumab improved PFS in BRAF V600–mutant melanoma brain metastases compared to nivolumab plus ipilimumab.
- Median intracranial PFS was significantly longer in the triplet arm, indicating enhanced efficacy in controlling brain metastases.
- Overall survival rates were similar between the triplet and doublet regimens, suggesting further investigation is needed to optimize treatment strategies.